SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, has appointed veteran medical technology finance executive Sarah M. Romano as chief financial officer, effective August 3, 2026. The appointment adds public-company financial and capital markets experience as the surgical robotics developer continues its global expansion and advances regulatory initiatives.
Romano brings more than two decades of experience in public-company finance, capital markets, and medical technology, having raised more than $100 million during her career. She joins SS Innovations after serving as chief financial officer at Vicarious Surgical, another developer of robotic surgical technologies, where she oversaw financial and operational initiatives designed to reduce cash burn and strengthen the company’s balance sheet.
The appointment comes as SS Innovations continues pursuing U.S. FDA clearance for its SSi Mantra surgical robotic system while expanding internationally. The company recently graduated the inaugural class of its SS International Centre for Robotics Surgery (SSICRS) cardiac robotic surgery training program, which underscores the company’s emphasis on surgeon education alongside technology deployment.
SSICRS welcomed 33 healthcare professionals from seven countries, highlighting the growing global interest in robotic surgery and the company’s commitment to training surgeons in advanced minimally invasive procedures. The program aims to build a skilled workforce capable of utilizing the SSi Mantra system effectively, which is crucial for the technology’s adoption in new markets.
With Romano’s financial expertise, SS Innovations is well-positioned to navigate the capital-intensive process of bringing a robotic surgical system to market, particularly in the U.S., where regulatory approval from the FDA is a key milestone. The company’s global expansion strategy includes partnerships and training initiatives to establish a foothold in regions with increasing demand for robotic surgery, such as Asia and Latin America.
The importance of this announcement lies in the strategic strengthening of SS Innovations’ leadership team at a critical juncture. As the company prepares for FDA review (https://nnw.fm/yY4UM) and scales its international operations, having a CFO with proven experience in raising capital and managing public-company finances is vital. Romano’s track record of raising over $100 million and her background at Vicarious Surgical provide confidence in SSII’s ability to secure necessary funding and execute its growth plans.
For investors, the appointment signals a focus on financial discipline and strategic capital allocation, which are essential for long-term success in the competitive surgical robotics market. The company’s commitment to surgeon training through SSICRS also differentiates it from competitors, as it addresses a critical barrier to adoption: the need for skilled surgeons to operate the technology. As robotic surgery continues to expand globally, SS Innovations aims to capture market share by combining technological innovation with education and support.
Additional information about SSII is available in the company’s newsroom at https://ibn.fm/SSII. For full terms of use and disclaimers, visit http://IBN.fm/Disclaimer.
